Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Gressenberger, P; Jud, P; Kovacs, G; Kreuzer, S; Brezinsek, HP; Guetl, K; Muster, V; Kolesnik, E; Schmidt, A; Odler, B; Adelsmayr, G; Neumeister, P; Brcic, L; Zenz, S; Weber, K; Gary, T; Brodmann, M; Graninger, WB; Moazedi-Fürst, FC.
Rituximab as a Treatment Option after Autologous Hematopoietic Stem Cell Transplantation in a Patient with Systemic Sclerosis.
J Pers Med. 2021; 11(7):
Doi: 10.3390/jpm11070600
(- Case Report)
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Gressenberger Paul Georg
- Co-Autor*innen der Med Uni Graz
- Adelsmayr Gabriel
- Brcic Luka
- Brezinsek Hans-Peter
- Brodmann Marianne
- Gary Thomas
- Graninger Winfried
- Gütl Katharina
- Jud Philipp
- Kielhauser Sonja
- Kolesnik Ewald
- Kovacs Gabor
- Moazedi-Fürst Florentine
- Nemecz Viktoria
- Neumeister Peter
- Odler Balazs
- Schmidt Albrecht
- Weber Kurt
- Zenz Sabine
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Systemic sclerosis (SSc) is an intractable autoimmune disease characterized by vasculopathy and organ fibrosis. Autologous hematopoietic stem cell transplantation (AHSCT) should be considered for the treatment of selected patients with rapid progressive SSc at high risk of organ failure. It, however, remains elusive whether immunosuppressive therapies such as rituximab (RTX) are still necessary for such patients after AHSCT, especially in those with bad outcomes. In the present report, a 43-year-old man with diffuse cutaneous SSc received AHSCT. Despite AHSCT, SSc further progressed with progressive symptomatic heart failure with newly developed concomitant mitral and tricuspid valve insufficiency, thus the patient started on RTX 8 months after AHSCT. Shortly after initiation of RTX, clinical symptoms and organ functions ameliorated subsequently. Heart valve regurgitations were reversible after initiation of RTX treatment. Currently, the patient remains in a stable condition with significant improvement of clinical symptoms and organ functions. Reporting about therapies after AHSCT in SSc is a very important issue, as randomized controlled trials are lacking, and therefore this report adds to evidence that RTX can be considered as a treatment option in patients with SSc that do not respond to AHSCT.
- Find related publications in this database (Keywords)
- systemic sclerosis
- rituximab
- autologous hematopoietic stem cell transplantation